fatty15 Review: C15:0 Evidence, Ingredients and Cost

fatty15 is a straightforward C15:0 capsule sold with ambitious metabolic and healthy-aging claims. The ingredient has early human research, but the evidence does not establish this supplement as a weight-loss treatment, a way to reverse aging or a substitute for prescribed care. Its appeal depends on how much you value trying an emerging ingredient at a recurring premium price.

This research-based review covers the original 100 mg capsules sold in the United States. We examined the official label, current purchase options and primary human studies. We have not personally tested fatty15 or measured changes in sleep, appetite or blood results.

What is in fatty15?

C15:0, also called pentadecanoic acid, is an odd-chain saturated fatty acid. The official capsule panel lists one capsule per serving and 100 mg of the branded FA15 ingredient. No Daily Value is established. Other ingredients are hypromellose and microcrystalline cellulose ¹. Those details make this a relatively simple formula, rather than a multivitamin, probiotic or fiber supplement.

There is a small but useful distinction between the marketing and the panel. The website describes the product as having one ingredient and no fillers, while the displayed label also names two other ingredients. We would use the actual panel when checking suitability. The pictured panel says 30 servings per container; the starter-kit offer contains 90 capsules ¹².

A clearly disclosed ingredient amount is an advantage. It lets a shopper compare the bottle with research instead of trying to infer a dose hidden inside a blend. It does not, by itself, tell us which benefits are likely or whether an ongoing purchase is worthwhile.

What have human trials shown?

A 2024 randomized, double-blind trial included 30 young adults with overweight or obesity: 20 received 200 mg C15:0 daily and 10 received placebo for 12 weeks. Its primary objective was the change in circulating C15:0, which increased with supplementation. No significant adverse events occurred ³. The study amount was twice the 100 mg in one original fatty15 capsule; this comparison describes the research, not a recommendation to change a serving.

The paper also reported liver-enzyme and hemoglobin findings among participants who reached a specified blood concentration. That analysis grouped people according to their response after treatment. It is less persuasive for proving a benefit than a clear comparison between the originally randomized groups. A small, short study focused on blood levels cannot establish broad claims about preventing diabetes, losing weight or extending life ³.

The TANGO randomized trial adds a different perspective. It enrolled 88 Chinese women with fatty liver disease into a Mediterranean-style adapted diet with C15:0, the diet without C15:0, or a usual-diet control for 12 weeks. Both diet groups improved weight and liver fat more than the control. The investigators reported an additional LDL-cholesterol reduction and a microbiome change with C15:0 ⁴.

That is useful preliminary evidence, but it is not a trial of the current fatty15 purchase plan in a general population. The dietary intervention matters. The findings do not establish that a capsule alone reproduces the weight or liver-fat changes, nor does one bacterial-abundance change prove better digestion.

Associations and cellular research need context

A higher blood concentration of a nutrient can accompany better health without being the reason for it. Diet, activity, other health differences and the body's handling of fats can influence the association. A supplement purchase asks a more practical question: does adding this particular product improve an outcome compared with not adding it?

A 2026 analysis examined C15:0 in the CARDIA and ARIC cohorts. Higher concentrations were modestly associated with lower blood pressure and hypertension risk, but not incident cardiovascular disease. Its genetic analysis did not support a causal cardiovascular benefit ⁵. This is not definitive proof that supplementation can never help; it is a reason to avoid presenting an observational association as a settled supplement benefit.

The same caution applies to cellular pathways. Activity in a laboratory can suggest what to study next. It does not tell a consumer how much better they will feel, whether a symptom will improve or how long they will live. Our assessment is that fatty15 remains an optional purchase with uncertain personal benefit.

Is C15:0 essential, or an omega-3 replacement?

We would not treat an essential-nutrient claim as proof that everyone needs a C15:0 capsule. NIH identifies alpha-linolenic acid and linoleic acid as established essential fatty acids. C15:0 is chemically different from omega-3 fatty acids such as EPA and DHA ⁶. A product's cellular comparison with EPA does not establish that it can replace a prescribed omega-3 medicine or meet the same nutritional purpose.

This matters when choosing where to spend a supplement budget. If a clinician recommended something for a specific reason, an advertisement about a different fat is not enough to make an equivalent substitution. Bring the label and the reason for the existing recommendation into that conversation.

Price and subscription terms

The reviewed US offer uses US dollars. Free US shipping is advertised; applicable taxes can change the checkout total. These per-capsule figures are arithmetic using the listed quantities and are not promised health outcomes ².

The 90-day subscription refills at $119.95 every 90 days. The $49.95 trial option also enrolls into 90-day refills at $119.95. A displayed monthly equivalent does not mean monthly billing. The annual kit contains 360 capsules, which is fewer than 365 daily servings; budget around the quantity you actually receive ².

Subscriptions can be canceled through the account. The brand's FAQ estimates in-stock processing at one to three business days and delivery at five to seven business days after shipping; these are estimates rather than a delivery commitment ⁷.

The refund window is shorter than the starter supply

The refund policy gives eligible first-time direct purchases a 30-day request window measured from the order date. It covers the first 30-day trial kit or 90-day starter kit, with important exclusions: annual and six-month kits, subscription refills and later purchases do not qualify for that guarantee ⁸.

A 90-day supply therefore does not provide 90 days to decide whether to request a refund. The annual option lowers the cost per capsule but requires more money upfront and falls outside the stated guarantee. That trade-off deserves more attention than the headline discount.

Safety and our verdict

The small 12-week trial is reassuring within its limited setting; it cannot rule out uncommon effects or establish long-term safety for every population. FDA does not approve dietary supplements before sale, and manufacturing claims are not approval of effectiveness. FDA advises discussing supplements with a health professional because interactions can occur ⁹.

For a shopper interested in an emerging fatty acid, fatty15 offers a disclosed amount and understandable purchase options. For someone seeking relief from bloating, constipation or medication-related nausea, the research reviewed here does not establish that it addresses those problems. For weight management or a diagnosed metabolic condition, it should not displace evaluation or established care.

Our verdict: the formula is easier to understand than the breadth of the marketing. Consider the recurring cost, the narrow refund eligibility and the uncertainty of a personally meaningful benefit before committing to a large supply.